Bavarian Nordic is pursuing the development of active
immunotherapy targeting major cancers. Lead product candidates
comprise PROSTVAC® for prostate cancer and CV-301 for breast
cancer.
Both PROSTVAC® and CV-301 are primeboost vaccines
sequentially combining two different poxviruses (vaccinia and
fowlpox). Collectively, these two product candidates have been the
subject of over 30 clinical trials in more than 1,000 patients with
prostate, breast, lung, colorectal, gastric, pancreatic, ovarian
and other cancers. These extensive clinical studies suggest a
favourable safety and tolerability profile along with immunologic
responses directed against the relevant tumour-associated
antigens.
Encouraging results from Phase 2 studies with PROSTVAC®
demonstrate a clear survival benefit along with a very favourable
safety profile when compared to existing treatment options
(chemotherapy) in patients suffering from advanced prostate cancer.
Confirmatory Phase 3 studies are underway and are expected to form
the basis for the approval of the vaccine, thus fulfilling a large
unmet medical need.
